Curriculum Vitae · 2018. 6. 11. · Curriculum Vitae Page 2 . Development of systemic JIA patient simulation CME modules, 2017 . UCB . Safety Officer, Data Safety Monitoring Board,

Timothy Beukelman, MD, MSCE Curriculum Vitae

Page 1

Curriculum Vitae

Personal Information Name: Timothy G. Beukelman Citizenship: U.S.A. Foreign Languages: None Home Address: xxxx Birmingham, AL 35216 Home Phone: 205-306-xxxx Rank/Title: Associate Professor with Tenure, Division of Rheumatology Department: Pediatrics Secondary Appointment: Division of Clinical Immunology and Rheumatology, Department

of Internal Medicine Business Address: University of Alabama at Birmingham /

Children’s of Alabama 1600 7th Avenue South CPP 210 Birmingham, AL 35233-1711 205-638-9438 Email: xxx Hospital and Other (non-academic) Appointments 2008 – 2011 Alabama Children’s Rehabilitation Service, Pediatric Rheumatology Professional Consultantships Pediatric Education for Drug Safety (PEDS), University of North Carolina, Chapel Hill

Pediatric rheumatology expert panel member, 2007-2008 Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center Program Technical Expert Panel member, 2009 – 2010 McKesson Health Solutions

Expert reviewer of specialty pharmaceutical drug use algorithms, 2011, 2013-15 Novartis Systemic Juvenile Idiopathic Arthritis Advisory Board, 2012 Canakinumab Phase III Advisory Board, 2012 Systemic Juvenile Idiopathic Arthritis Advisory Board, 2013 Review of educational materials, 2013 Autoinflammatory Diseases Advisory Board, 2013 Systemic Juvenile Idiopathic Arthritis Advisory Board, 2014 Safety of Canakinumab and SJIA Disease Awareness Advisory Board, 2015 Understanding Ilaris Across the Disease Spectrum Advisory Board, 2017 Genentech/Roche Polyarticular and Systemic JIA Advisory Board, 2012 National Pediatric and Adult Rheumatology Advisory Board, 2014 Real World Data Evidence Advisory Board, 2015 Medscape Development of systemic JIA patient simulation CME modules, 2013


Page 2

Development of systemic JIA patient simulation CME modules, 2017 UCB Safety Officer, Data Safety Monitoring Board, 2013 – Crescendo Biosciences Juvenile Idiopathic Arthritis Advisory Board, 2013 Vindico Course Chair, “Updates in Systemic JIA” CME symposium, 2014 Spire Learning

Program Chair and Lecturer, “Updates and Guidance on the Management of JIA” CME teleconferences, 2014

Projects in Knowledge / @Point of Care Contributing Editor, JIA Current Treatment Strategies CME module, 2017 Medical Learning Institute / PeerView Institute

Course Director, “SJIA: Overcoming Challenges in Diagnosis and Management to Individualize Care and Achieve Treatment Goals” CME module, 2017

Sobi Chair, Data Safety Monitoring Board, 2017 – Bristol-Myers Squibb Rheumatology Collaborative Institute Advisory Board, 2017 Education 2008 M.S.C.E. University of Pennsylvania, Philadelphia, PA 2001 M.D. Washington University, Saint Louis, MO 1997 B.S. University of Illinois, Urbana-Champaign, IL Licensure Alabama (28137) Pennsylvania (MD424288) – inactive Ohio (82203) – inactive Board Certification American Board of Pediatrics – Pediatrics, 2004 American Board of Pediatrics – Pediatric Rheumatology, 2009 Post-Doctoral Training: 2004-2007 Fellow in Pediatric Rheumatology, The Children’s Hospital of Philadelphia, PA 2002-2004 Resident in Pediatrics, Cincinnati Children’s Hospital Medical Center, OH 2001-2002 Intern in Pediatrics, Cincinnati Children’s Hospital Medical Center, OH Academic Appointments 2007-2011 Assistant Professor of Pediatrics, Department of Pediatrics, Division of

Rheumatology, University of Alabama at Birmingham, AL 2011-2016 Associate Professor of Pediatrics, Department of Pediatrics, Division of

Rheumatology, University of Alabama at Birmingham, AL 2016 – Associate Professor of Pediatrics with Tenure, Department of Pediatrics, Division

of Rheumatology, University of Alabama at Birmingham, AL


Page 3

Awards/Honors 2015, 2017 American College of Rheumatology/Rheumatology Research Foundation

Pediatric Visiting Professor 2013 ACR/EULAR International Academic Rheumatology Exchange, Early Career

Investigator Delegate 2013 Member, American Pediatric Society 2008 – 2014 National Institute of Health (NIH) Loan Repayment Program for Clinical

Researchers 2007 University of Alabama Health Services Foundation General Endowment Fund

Scholar Award 2005, 2006 Fellows Scholarship Travel Fund, American College of Rheumatology 2005-2006 Ruth L. Kirschstein National Research Service Award (NRSA), National

Institutes of Health 2002 Pediatric Rheumatology Residents Program, American College of Rheumatology 1998 Dr. Lee B. and Virginia G. Harrison Scholars Program, Washington University 1997 Summa Cum Laude, Phi Beta Kappa, University of Illinois 1997 Highest Distinction for Senior Thesis, University of Illinois Professional Societies Jefferson County (AL) Medical Society, Member 2016 – Society for Pediatric Research/American Pediatric Society, Member 2013 – International Society for Pharmacoepidemiology, 2011 – Pediatric Special Interest Group, 2012 – American College of Rheumatology (ACR), Fellow 2007 –

ACR/EULAR Exchange, Early Career Investigator Delegate, 2013 Strategic Planning Task Force, 2013 Pediatric Rheumatology Symposium (PRSYM) Planning Committee, 2012-14; 2015-17 2020 Task Force Member, 2011 – 2013 Practice Guidelines Subcommittee Member, 2010 – 2016

Chair, Practice Guidelines Subcommittee, 2013 – 2016 Quality of Care Committee Member, 2013 – 2016

Childhood Arthritis & Rheumatology Research Alliance (CARRA), 2005 – Juvenile Idiopathic Arthritis Registry Workgroup, 2009 CARRAnet Data/Sample Share Committee, 2012 – 2016 Juvenile Idiopathic Arthritis Research Committee Member, 2005 – Vice-Chair, JIA Research Committee, 2012 – 2013 Chair, JIA Research Committee, 2013 – 2016 Juvenile Idiopathic Arthritis Protocol Evaluation Subcommittee Chair, 2012 – 2013 Scientific Director, CARRA Registry, 2014 – Alabama Society for the Rheumatic Diseases, 2007 – Tri-State (PA, DE, NJ) Pediatric Rheumatology Study Group, 2004-2007 Philadelphia Rheumatism Society, 2004-2007 Memberships UAB Deep South Musculoskeletal Center for Education and Research on Therapeutics (CERTs)


Page 4

Investigator, 2007 – 2016 Pediatric Rheumatology Care and Outcome Improvement Network (PR-COIN) Steering committee member, 2008 – 2012 Pediatric Rheumatology Collaborative Study Group (PRCSG) Member, 2012 – Validated Joint Assessor (2013) UAB Center for Outcomes and Effectiveness Research and Education (COERE) Member, 2012 – Councils and Committees FDA Workshop: “Developing a Consolidated Pediatric Rheumatology Observational Registry” Session Co-Chair, 2009 Juvenile Idiopathic Arthritis Quality Measures Work Group Member, 2008 – 2010 Juvenile Idiopathic Arthritis Consolidated Registry (JIA CoRe) Task Force

Executive Committee; Steering Committee Chair, Registry Design Subcommittee

American College of Rheumatology Practice Guidelines Subcommittee Member, 2010 – 2016 Chair, 2013 – 2016 CTSA Consortium Child Health Oversight Committee Member, 2010 – 2014 American College of Rheumatology 2020 Task Force Member, 2011 – 2013 Lupus Foundation of America

Grant Reviewer, 2011, 2012, 2013, 2014, 2015 American College of Rheumatology Annual Scientific Meeting Abstract Selection Committee Reviewer, 2011, 2014, 2015 American College of Rheumatology Criteria for Appropriateness of Ultrasound in Rheumatology Task force panel member, 2011 CARRA JIA Protocol Evaluation Subcommittee Chair, 2012 – 2013 Member, 2012 – 2016 CARRAnet Data/Sample Share Committee Member, 2012 – 2016 International Conference on Pharmacoepidemiology and Therapeutic Risk Management Abstract Reviewer, 2012, 2014, 2015, 2016 Poster Walk Leader, 2012 Swiss National Science Foundation Research Proposal Reviewer, 2012 CARRA JIA Research Committee Vice Chair, 2012 – 13 Chair, 2013 – 2016 ACR Pediatric Rheumatology Symposium (PRSYM) Planning Committee Member, 2012 – 2014; 2015 – 2017 Abstract Reviewer, 2014


Page 5

American College of Rheumatology Strategic Planning Task Force Member, 2013 German Federal Ministry of Education and Research Research Proposal Reviewer, 2013 Dutch Arthritis Association Research Proposal Reviewer, 2013, 2014 American College of Rheumatology Quality of Care Committee Member, 2013 – 2016 NIH/National Institute of Child Health and Human Development (NICHD) Pediatric Terminology Harmonization Initiative Subject Matter Expert, 2014 – 2015 Centers for Disease Control and Prevention: Developing a National Public Health Agenda for Lupus Invited Expert, 2015 National Institutes of Health(NIH)/NIAMS Loan Repayment Program Scientific Reviewer, 2016, 2017 American College of Rheumatology/Rheumatology Research Foundation Scientific Reviewer for Innovative Research Awards, 2016 – 2018 Arthritis Foundation Delivering on Discovery Solicitation Scientific Reviewer, 2016 University Activities Co-Chair, Scientific Review Committee for Pediatric Rheumatology, 2007- Poster Judge, Medical Student Research Day, 2008 Reviewer, Kaul Pediatric Research Institute grant applications, 2010, 2013 Reviewer, UAB PCOR K12 grant applications, 2014 Mentor, UAB CCTS Short-Term Research Training Program in Patient Oriented Research, 2014 Reviewer, HSF-GEF Clinical Care Initiative Review Committee, 2014-2017 Children’s of Alabama/Dept of Pediatrics Ambulatory Physician Advisory Group, 2015-2017 Editorial Board Memberships Editorial Board: Journal of Rheumatology (2012 – Ad-Hoc Peer Reviewer: New England Journal of Medicine

The Lancet Journal of the American Medical Association (JAMA) Arthritis & Rheumatology Annals of the Rheumatic Diseases

Arthritis Care & Research Arthritis Research & Therapy

Rheumatology Journal of Rheumatology

Pediatric Rheumatology Lupus

Pharmacoepidemiology and Drug Safety Medical Care


Page 6

Value in Health Pediatrics Journal of Pediatrics

Clinical and Experimental Rheumatology Nature Reviews Rheumatology Journal of Clinical Rheumatology Seminars in Arthritis and Rheumatism Scandinavian Journal of Rheumatology Clinical Rheumatology Rheumatology International

Expert Review of Clinical Immunology Rheumatic & Musculoskeletal Diseases (RMD) Open Clinical Journal of the American Society of Nephrology Archives of Disease in Childhood Pediatric Drugs Technology Assessment at Sick Kids (TASK); The

Hospital for Sick Children, Toronto, Canada Major Research Interests Optimizing the treatment of juvenile idiopathic arthritis using various clinical research methods including retrospective analysis of observational data, prospective observational data collection and analysis, quality improvement, clinical treatment guideline development, decision analysis, and clinical trials. Teaching Experience Educational Lectures:

1. “Pediatric Rheumatology Board Review”, Pediatric Resident Educational Conference, Nicklaus Children’s Hospital, Miami, Florida, January 2018.

2. “Pediatric Vasculitis”, UAB Pediatric Resident Educational Conference, November 2013. 3. “Juvenile Idiopathic Arthritis”, UAB Rheumatology Fellow Education Conference,

October 2012. 4. “Pediatric Vasculitis”, UAB Pediatric Resident Educational Conference, March 2012. 5. “Juvenile Idiopathic Arthritis”, UAB Rheumatology Fellow Educational Conference,

October 2011. 6. “Pediatric Vasculitis”, UAB Pediatric Resident Educational Conference, September

2010. 7. “Assorted Rheumatic Disorders”, UAB Pediatric Resident Educational Conference,

September 2009. 8. “Pediatric Rheumatology”, UAB Third Year Medical Student Pediatric Clerkship

Lecture, (Recurring every 8 weeks) 2008 – 2009. 9. “Juvenile Idiopathic Arthritis”, UAB First Year Medical Student Lecture, May 2008. 10. “Auto-Inflammatory Fever Syndromes”, UAB Rheumatology Fellow Educational

Conference, April 2008. 11. “Vasculitis”, UAB Pediatric Resident Educational Conference, February 2008. 12. “Rheumatology in the Pediatric Emergency Department”, UAB Pediatric Emergency

Medicine Fellows Educational Conference, October 2007.


Page 7

Mentoring of Trainees and Junior Faculty:

1. Courtney Crayne, UAB Pediatric Rheumatology Fellow, 2016-19. 2. Daniel Horton, Rutgers Robert Wood Johnson Medical School Postdoctoral Research

Fellow in Pediatric Rheumatology, 2015 - . Secondary research mentor for career development award.

3. Jie Zhang. UAB Assistant Professor of Epidemiology, 2010 - . Secondary research mentor for career development award application.

4. Lauren Beth Shipman, UAB Pediatric Rheumatology Fellow, 2014 – 2017. Primary research mentor.

5. Sonja Falvey, University of Mississippi Pharmacy Student. UAB CCTS Short-Term Research Training Program in Patient Oriented Research, 2014.

6. Emily Fox, Stanford University Pediatric Rheumatology Fellow. ACR-CARRA AMIGO Mentee, 2013-15.

7. Robert Richter, UAB Pediatric Hospitalist Fellow, 2013-14. Scholarship Oversight Committee member.

8. Roxanna Sabghi, University of Alabama Medical Student. Scholarly Activity mentor, 2013.

9. Melissa Lerman, Instructor, Children’s Hospital of Philadelphia. ACR-CARRA AMIGO Mentee, 2012-15.

10. Melissa Mannion, UAB Pediatric Rheumatology Fellow, 2011 – 2014. Primary research mentor. UAB Instructor, 2014. UAB Assistant Professor, 2015. Research mentor for career development award application.

11. Ajay Tambralli, University of Alabama Medical Student. Scholarly Activity mentor, 2012.

12. Ashley Shafferman, University of Alabama Medical Student. Scholarly Activity mentor 2012.

13. Nadia Luca, Hospital for Sick Children, Toronto, Pediatric Rheumatology Fellow. 14. Heather Burnett, University of Toronto Health Policy Management and Evaluation

Masters of Science Student. External reviewer on Master’s thesis review committee. 15. Katherine Donnithorne, University of Alabama Medical Student and Ophthalmology

Resident. Recipient of Department of Pediatrics Russell Cunningham Memorial Research Scholars Program, Summer 2008. Award for outstanding poster, Medical Student Research Day, 2008. Scholarly Activity mentor, 2010. Resident research elective mentor, 2012.

16. University of Alabama School of Medicine Summer Health Enrichment Program. Clinical mentor for undergraduate pre-medical students, Summer 2008.

17. UAB Adult Rheumatology Fellows. Direct supervision and education of adult rheumatology fellows during their required training in pediatric rheumatology.

Fellows trained to date: Allyson McDonough, Maria Danila, Zang Song, Elizabeth Perkins, Bita Shakoory, Ajoy Chhabra, Bilal Khan, Iris Navarro, Quynh Bao, Rebecca Belsom, Archana Jain, Yong Hwang

Major Lectures and Visiting Professorships (International in Bold)


Page 8

1. American College of Rheumatology/Rheumatology Research Foundation Pediatric Visiting Professorship. Nicklaus Children’s Hospital, Miami, Florida, January 2018.

2. “ Diagnosis and Management of Common Pediatric Rheumatology Conditions”. Nicklaus Children’s Hospital Grand Rounds, Miami, Florida, January 2018.

3. “Pediatric Rheumatology Clinical Research Year in Review”. American College of Rheumatology Annual Scientific Meeting, San Diego, California, November 2017.

4. “The Need for Validation of Pediatric Outcomes”. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 2017.

5. “Treatment of Juvenile Idiopathic Arthritis: State of the Art”. American College of Rheumatology Pediatric Rheumatology Symposium (PRSYM), Houston, Texas, May 2017.

6. American College of Rheumatology/Rheumatology Research Foundation Pediatric Visiting Professorship. Florida Hospital for Children, Orlando, Florida, January 2016.

7. “Diagnosis and Management of Common Pediatric Rheumatology Conditions”. Florida Hospital Pediatric Grand Rounds, Orlando, Florida, January 2016.

8. “Overview of Data Sources and Methods to Conduct Studies of the Pediatric Rheumatic Diseases”. American College of Rheumatology Annual Scientific Meeting, San Francisco, California, November 2015.

9. “Resources for Tracking Outcomes: Administrative Data”. American College of Rheumatology Clinical Research Conference, San Francisco, California, November 2015.

10. “The UAB CCTS Program: Opportunities for Pediatric Clinician Scientists”. University of Alabama at Birmingham, Department of Pediatrics/Children’s of Alabama Grand Rounds, Birmingham, Alabama, February 2015.

11. “The Recommended Management of Systemic JIA”. International Symposium on Translational Approaches to Autoinflammatory Diseases, Münster, Germany, May 2014.

12. “Investigating the Safety of Treatments for Juvenile Arthritis”. Albert Einstein College of Medicine, Department of Pediatrics/Children’s Hospital at Montefiore Grand Rounds, Bronx, New York, March 2014.

13. “Investigating Adverse Effects of Therapy Using Medicaid Claims Data”. University of Minnesota, Department of Pediatrics/Amplatz Children’s Hospital Grand Rounds, Minneapolis, Minnesota, January 2014.

14. “ACR Recommendations for the Treatment of JIA: Overview and Commentary”. Pan Arab Rheumatology Conference, Dubai, United Arab Emirates, January 2014.

15. “Juvenile Idiopathic Arthritis: Review and Update”. Rheumatology Nurses Society Annual Conference, Nashville, Tennessee, August 2013.

16. “Current Approaches: Role of IL-6 and IL-1 Inhibiting Agents in Systemic JIA Management”. Pediatric Rheumatology Workshop, XVII Summit of Pediatricians of Russia, Moscow, Russian Federation, February 2013.


Page 9

17. “Role of New IL-1 and IL-6 Inhibiting Agents in Systemic Juvenile Idiopathic Arthritis”. American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2012.

18. “A New Model for the Assessment of Disease-Specific Pediatric Drug Safety: The Childhood Arthritis and Rheumatology Research Alliance Consolidated Registry (CARRA-CoRe)”. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, August 2012.

19. “Treatment of Juvenile Idiopathic Arthritis”. Mexican Congress of Rheumatology, San Luis Potosi, Mexico, February 2012.

20. “The Treatment of Juvenile Idiopathic Arthritis”. Mexican College of Rheumatology International Symposium on Rheumatoid Arthritis, Aguascalientes, Mexico, October 2011.

21. “2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis”. University of Toronto Intracity Rheumatology Conference, Toronto, Canada, September 2011.

22. “2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis”. Danish Pediatric Rheumatology Society Scientific Meeting, Nyborg, Denmark, March 2011.

23. “Malignancy and Juvenile Idiopathic Arthritis: What is the Risk?”. Danish Pediatric Rheumatology Society Scientific Meeting, Nyborg, Denmark, March 2011.

24. “Investigating the Incidence of Serious Adverse Events Using Medicaid Billing Data: The Risk of Malignancy and Hospitalized Infection in Juvenile Idiopathic Arthritis”. University of Alabama at Birmingham, Department of Pediatrics/Children’s of Alabama Grand Rounds, Birmingham, Alabama, January 2011.

Grant Support Current:

1. PCORI, PPRN Demonstration Project. Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies. PI: Curtis/Beukelman. 2016 – 2019. $2,500,000.

2. CARRA (Genentech). Investigator-initiated. First-line Options for Systemic JIA Treatment (FROST). PI: Kimura/Beukelman. 2016 – 2020. $1,716,417.

3. PCORI, Patient Powered Research Networks. The Patients, Advocates, and Rheumatology Teams Network for Research and Service (PARTNERS). PI: Schanberg. Role: Investigator. 2015 – 2018. $1,391,099.

4. Childhood Arthritis and Rheumatology Research Alliance (CARRA). Scientific Director of CARRA Registry. PI: Beukelman [service agreement]. 2014 – 2019. $163,321.

Pending: Past:

1. Agency for Healthcare Research and Quality (AHRQ), U18. Deep South Arthritis and Musculoskeletal Center for Education and Research on Therapeutics (CERTs). PI: Saag. Role: Demonstration project PI. 2011 – 2016. $4,123,322.


Page 10

2. Childhood Arthritis and Rheumatology Research Alliance (CARRA). Chair, Juvenile Idipathic Arthrtis Research Committee. PI: Beukelman [service agreement]. 2015 – 2016. $12,589.

3. NIH/NIAMS, U34. The Effectiveness of Methotrexate to Prevent Extension of Early Limited JIA. PI: Beukelman. 2014 – 2015. $356,864.

4. Patient Centered Outcomes Research Institute (PCORI), Patient Powered Research Networks. The Patients, Advocates, and Rheumatology Teams Network for Research and Service (PARTNERS). PI: Schanberg. Role: Investigator. 2014 – 2015. $1,008,490.

5. NIH/NIAMS, L30 (Loan Repayment Program for Clinical Researchers). “Optimizing the Treatment of Childhood Arthritis”. PI: Beukelman. 2008 – 2010; competitive renewals 2010 – 2012 and 2012 – 2014. $85,260.

6. Pfizer. “Usage of NSAIDs, Glucocorticoids, and DMARDs in the Treatment of Juvenile Idiopathic Arthritis in the United States.” PI: Beukelman. 2012 – 2013. $75,847.

7. NIH/NCRR (University of Alabama at Birmingham, Center for Clinical and Translational Science), KL2 Mentored Career Development Award. “The Risk of Serious Infection in Juvenile Idiopathic Arthritis”. PI: Guay-Woodford/Beukelman. 2009 – 2013. $540,000.

8. NIH/NIAMS (Cincinnati Children’s Hospital), P60. Cincinnati Multidisciplinary Clinical Research Center: Improved Understanding of the Biology and Use of TNF Inhibition in Children with JIA. PI: Glass/Lovell. Role: Site PI. 2011 – 2013. $7,678,248 [$5865]

9. NIH/NIAMS (Duke University), ARRA Grand Opportunity. Childhood Arthritis and Rheumatology Research Alliance Network (CARRAnet): Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology. PI: Schanberg. Role: Site PI. 2010 – 2012. $6,824,989.

10. Agency for Healthcare Research and Quality (AHRQ), U18. Deep South Musculoskeletal Center for Education and Research on Therapeutics. PI: Saag. Role: Investigator. 2006 – 2011. $3,748,745.

11. Agency for Healthcare Research and Quality (AHRQ), U18. “Safety Assessment of Anti-TNF Agents Used in Autoimmune Disease”. PI: Saag. Role: Investigator. 2008-2011. $2,243,600.

12. American College of Rheumatology. “Guidelines for the Treatment of Juvenile Idiopathic Arthritis”. PI: Beukelman. 2009 – 2010. $100,000.

Volunteer Work

Arthritis Foundation Juvenile Arthritis Family Forum. Guest speaker. Camp M.A.S.H., Alabama. Volunteer 2007. Camp physician 2010. Camp JRA, Pennsylvania. Camp physician July 2005.

Saturday Neighborhood Health Center, Washington University. 2000-01. Young Scientist Program, Washington University. 1997-98. Bibliography Manuscripts Published:

1. Lovell DJ, Johnson AL, Huang B, Gottlieb BS, Morris PW, Kumira Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA,


Page 11

Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, Wagner-Weiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Mehta J, Ting TV, Verbsky JW, Eberhard AB, Spalding S, Chen C, Giannini EH. Risk, timing and predictors of disease flare after discontinuation of anti-tumor necrosis factor (TNF) therapy in children with polyarticular forms of juvenile idiopathic arthris (JIA) in clinical inactive disease. Arthritis Rheumatol. [published online 31 Mar 2018]

2. Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-line Options for Systemic JIA Treatment (FROST). Clinical Trials. [published online 1 Mar 2018]

3. Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion ML, Saag KG, Curtis JR. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. [published online 9 Feb 2018]

4. Mor-Vaknin N, Rivas M, Legendre M, Mohan S, Yuanfan Y, Mau T, Johnson A, Huang B, Zhao L, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit BS, Shishov M, Jung LK, Cassidy EA, Prahalad S, Passo MH, Beukelman T, Mehta J, Giannini EG, Adams BS, Lovell DJ, Markovitz DM. High levels of DEK autoantibodies in sera of polyarticular JIA and in early flare following cessation of anti-TNF therapy. Arthritis Rheumatol 2018; 70:594-605. [published online 29 Dec 2017]

5. Stoll ML, Grubbs JA, Beukelman T, Mannion ML, Jester TW, Cron RQ, Crain MJ. Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: A retrospective study. Pediatr Rheumatol Online J 2017 Nov 9; 15:79.

6. Weiss PF, Xiao R, Brandon TG, Pagnini I, Wright TB, Beukelman T, Morgan E, Feudtner C. Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: the first year after diagnosis. J Rheumatol 2018; 45:107-14. [published online 15 Sep 2017]

7. Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO. Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: Report from a special interest group at OMERACT 2016. J Rheumatol 2017; 44:1884-88. [published online 15 Aug 2017]

8. Mehta J, Beukelman T. Biologic agents in the treatment of childhood-onset rheumatic disease. J Pediatr 2017; 189:31-9. [published online 13 Jul 2017]

9. Falvey S, Shipman LE, Ilowite N, Beukelman T. Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017 Jun 19; 15:52.

10. Curtis JR, Xie F, Smith C, Saag KG, Chen L, Beukelman T, Mannion MM, Yun H, Kertesz S. Changing trends in opioid use among U.S. rheumatoid arthritis patients. Arthritis Rheumatol 2017; 69:1733-40. [published online 21 Jun 2017]


Page 12

11. Gmuca S, Xiao R, Brandon TG, Pagnini I, Wright TB, Beukelman T, Morgan E, Weiss PF. Multicenter inception cohort of enthesitis-related arthritis: Variation in disease charactertics and treatment approches. Arthritis Res Ther 2017 May 2; 19:84.

12. Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Guzman J, Horneff G, Klein A, Klotsche J, Magnusson B, Minden K, Munro JE, Niewerth M, Nordal E, Ruperto N, Santos MJ, Schanberg LE, Thomson W, van Suijlekom-Smit L, Wulffraat N, Hyrich K. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: Challenges and opportunities. Pediatr Rheumatol Online J 2017 Apr 19; 15:31.

13. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE. The new Childhood Arthritis and Rheumatology Research Alliance Registry: Design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J 2017 Apr 17; 15:30.

14. Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, Graham TB, Ibara M, Ilowite N, Klein-Gitelman M, Onel K, Prahalad S, Punaro M, Ringold S, Toib D, Van Mater H, Weiss JE, Weiss PF, Schanberg LE. Pilot study comparing Childhood Arthritis and Rheumatology Research Alliance (CARRA) Conensus Treatment Plans. Pediatr Rheumatol Online J 2017 Apr 11; 15:23.

15. Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and approaches for withdrawing drugs for children with clinically inactive non-systemic JIA: a survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol 2017; 44:352-60. [published online 1 Feb 2017]

16. Curtis JR, Xie F, Mackey D, Gerber N, Bharat A, Beukelman T, Saag KG, Chen L, Nowell B, Ginsberg S. Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. BMC Musculoskelet Disord 2016 Sep 26; 17:405.

17. Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2016 Sep 22; 18:210.

18. Mannion ML, Xie F, Baddley J, Chen L, Curtis JR, Saag KG, Zhang J, Beukelman T. Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J 2016 Sep 5; 14:49.

19. Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, Schwartz G, Bayoumi AM. Cost-effectiveness analysis of first-line treatment with biologics in polyarticular juvenile idiopathic arthritis. Arthritis Care Res 2016; 68:1803-11. [published online 5 Apr 2016]

20. Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, De Benedetti F, Grom AA, Cron RQ. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol 2016; 196: 2492-503. [published online 15 Feb 2016] [cited 5 times]


Page 13

21. Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelonoma skin cancer. JAMA Dermatol 2016; 152:164-72. [published online 28 Oct 2015] [cited 11 times]

22. Stoll ML, Vaid YN, Gurash S, Beukelman T, Waite PD, Cron RQ. Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis. J Rheumatol 2015; 42:2155-9. [cited 1 time]

23. Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents among Medicare rheumatoid arthritis patients. Arthritis Rheumatol 2016; 68:55-66. [published online 28 Aug 2015] [cited 14 times]

24. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol 2015; 42:541-6. [published online 15 Jan 2015] [cited 11 times]

25. Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR. Impact of biologics with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res 2015; 67:624-32. [published online 4 Nov 2014] [cited 9 times]

26. Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, Lopez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE. A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project (EDSSP). Arthritis Care Res 2015; 67:529-37. [published online 20 Oct 2014] [cited 3 times]

27. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, Saag KG, Beukelman T, Wintrhop K, Baddley JW, Curtis JR. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease modifying therapy. Arthritis Care Res 2015; 67:731-6. [published online 8 Sep 2014] [cited 14 times]

28. Mannion ML, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. J Rheumatol 2014; 41:2078-84. [published online 1 Aug 2014] [cited 3 times]

29. Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, Morgan DeWitt E, Pagnini I, Wright TB, Wallace CA. Development and retrospective validation of the juvenile spondyloarthropathy disease activity (JSpADA) index. Arthritis Care Res 2014; 66:1775-82. [published online 21 Jul 2014] [cited 13 times]


Page 14

30. Mannion ML, Beukelman T. Risk of malignancy associated with biologic agents in pediatric rheumatic disease. Curr Opin Rheumatol 2014; 26:538-42. [published online 9 Jul 2014] [cited 5 times]

31. Curtis JR, Zhang J, Xie F, Beukelman T, Chen L, Fernandes J, Ginsberg S, Spettell C, Yun H, Saag KG, Schiff M. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res 2014; 66:1604-11. [published online 18 Jun 2014] [cited 8 times]

32. Kimura Y, Morgan DeWitt E, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML. Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis [Letter]. Arthritis Care Res 2014; 66:1430-1. [published online 9 Apr 2014] [cited 11 times]

33. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep 2014; 6:21. [published online 1 Apr 2014] [cited 12 times]

34. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K, Baddley JW, Curtis JR. Risk of hospitalized infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 2015; 74:1065-71. [published online 7 March 2014] [cited 12 times]

35. Shafferman A, Fontaine KR, Cron RQ, Beukelman T. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 2014; 41:113-8. [published online 1 Dec 2013] [cited 2 times]

36. Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace C, Ilowite N, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O’Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulfraat NM, Sandborg CI. Using registries to identify adverse events in rheumatic diseases. Pediatrics 2013; 132:e1384-94. [published online 21 Oct 2013] [cited 8 times]

37. Vaid YN, Dunnavant FD, Royal SA, Beukelman T, Stoll ML, Cron RQ. Imaging of the temporomandibular joint in juvenile idiopathic arthritis. Arthritis Care Res 2014; 66:47-54. [published online 19 Sep 2013] [cited 20 times]

38. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 2013; 65:1551-63. [cited 95 times]

39. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol 2013; 40:1749-55. [published online 15 Aug 2013]. [cited 19 times]

40. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Non-viral opportunistic infections in new users of tumor necrosis factor inhibitor


Page 15

therapy: Results of the safety assessment of biologic therapy (SABER) study. Ann Rheum Dis 2014; 73:1942-8. [published online 13 Jul 2013]. [cited 16 times]

41. Donnithorne KJ, Read RW, Lowe R, Weiser P, Cron RQ, Beukelman T. Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: A case report. Pediatr Rheumatol Online J 2013; 11:25. [cited 10 times]

42. Ringold S, Beukelman T, Nigrovic PA, Kimura Y. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013; 40:936-42. [published online 15 Apr 2013]. [cited 18 times]

43. Hurd A, Beukelman T. Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep 2013; 15:327. [cited 6 times]

44. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887-95. [cited 82 times]

45. Beukelman T, Xie R, Baddley JW, Chen L, Delzell E, Grijalva CG, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2013; 65:1384-9. [published online 4 Mar 2013]. [cited 23 times]

46. Mannion ML, Beukelman T. What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep 2013; 15:310. [cited 5 times]

47. Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison to other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2012; 39:2341-51. [published online 15 Oct 2012]. [cited 20 times]

48. Haynes K, Beukelman T, Curtis JR, Herrinton L, Graham D, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune mediated diseases. Arthritis Rheum 2013; 65:48-58. [published online 10 Oct 2012]. [cited 43 times]

49. Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattey D, Baddley JW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR. Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic therapy (SABER) study. Am J Ophthalmol 2013; 155:183-9. [published online 8 Sep 2012]. [cited 22 times]

50. Mannion ML, Zolak M, Kelly DR, Beukelman T, Cron RQ. Sarcoidosis in a young child with Alagille syndrome: A case report. Pediatr Rheumatol Online J 2012; 10:32. [published online 31 Aug 2012].

51. Beukelman T, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39:1867-74. [published online 1 Aug 2012]. [cited 35 times]

52. Saag KG, Mohr PE, Esmail L, Mudano AS, Wright N, Beukelman T, Curtis JR, Cutter G, Delzell E, Gary LC, Harrington TM, Karkare S, Kilgore ML, Lewis CE,


Page 16

Moloney R, Oliveira A, Singh J, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon DH, Wallace R, Tunis SR. Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the Unites States. Contemp Clin Trials 2012; 33:1211-6. [published online 5 Jul 2012]. [cited 9 times]

53. Woolston SL, Beukelman T, Sherry DD. Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility. Pediatr Rheumatol Online J 2012; 10:17. [published online 20 Jun 2012]. [cited 5 times]

54. Stoll ML, Sharpe T, Beukelman T, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. J Rheumatol 2012; 39:1880-7. [published online 15 May 2012]. [cited 45 times]

55. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:2773-80. [published online 8 May 2012]. [cited 59 times]

56. Curtis JR, Xie F, Chen L, Munter P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res 2012; 64:1480-9. [published online 3 May 2012]. [cited 28 times]

57. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus H, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64:625-39. [cited 843 times]

58. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:1263-7. [published online 10 Feb 2012]. [cited 80 times]

59. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012; 64:1001-10. [published online 30 Jan 2012]. [cited 80 times]

60. Stoll ML, Good J, Sharpe T, Beukelman T, Young D, Waite PD, Cron RQ. Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. J Oral Maxillofac Surg 2012; 70:1082-7. [published online 21 Jan 2012]. [cited 38 times]

61. Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with


Page 17

selected rheumatic diseases. Arthritis Care Res 2012; 64:612-5. [published online 12 Dec 2011]. [cited 30 times]

62. Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNFα inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease. J Rheumatol 2011; 38:2675-81. [published online 15 Nov 2011]. [cited 25 times]

63. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331-9. [published online 6 Nov 2011]. [cited 162 times]

64. Fain ER, Atkinson GP, Weiser P, Beukelman T, Cron RQ. Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis. J Rheumatol 2011; 38:2272-3. [cited 5 times]

65. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E Patkar NM, Rassen J, Winthrop KL, Nourjah P, Saag KG. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20:1199-209. [published online 15 Sep 2011]. [cited 18 times]

66. Ashraf AP, Beukelman T, Pruneta-Deloche V, Kelly DR, Garg A. Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjögren’s syndrome. J Clin Endocrinol Metab 2011; 96:3302-7. [published online 31 Aug 2011]. [cited 4 times]

67. Baddley JW, Winthrop KL, Patkar NM, Delzell E, Beukelman T, Xie F, Chen L, Curtis JR. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis 2011; 17:1664-9. [published online 11 Aug 2011]. [cited 63 times]

68. Record JL, Beukelman T, Cron RQ. High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. Pediatr Rheumatol Online J 2011; 9:20. [cited 4 times]

69. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag K, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biologic agents. Ann Rheum Dis 2011; 70:1401-6. [published online 17 May 2011]. [cited 71 times]

70. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63:465-82. [cited 332 times]

71. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheum 2011; 38:180-1. [cited 34 times]


Page 18

72. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, Morgan DeWitt E, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care. A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res 2011; 63:10-16. [published online 14 Sep 2010] [cited 26 times]

73. Cron RQ, Beukelman T. Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA? [editorial comment]. Pediatr Rheumatol Online J 2010; 8:23. [cited 23 times]

74. Mehta J, Genin A, Brunner M, Scalzi LV, Mishra N, Beukelman T, Cron RQ. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis. Arthritis Rheum 2010; 62:2499-2509. [published online 6 May 2010]. [cited 12 times]

75. Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 2010; 21:1573-84. [published online 24 Nov 2009]. [cited 11 times]

76. Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, Beukelman T, Cron RQ. Rituximab therapy for severe refractory chronic Henoch-Schölein purpura. J Pediatr 2009; 155:136-9. [cited 40 times]

77. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V, Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43-7. [published online 15 Jan 2009]. [cited 75 times]

78. Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580-88. [cited 19 times]

79. Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. Clin Exp Rheumatol 2008; 26:700-3. [cited 15 times]

80. Behrens EM, Beukelman T, Gallo L, Sprangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania systemic onset juvenile arthritis registry (PASOJAR). J Rheumatol 2008; 35:343-8. [cited 69 times]

81. Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 2007; 34:1918-24. [cited 14 times]

82. Cahill AM, Cho SS, Baskin KM, Beukelman T, Cron RQ, Kaye RD, Towbin RB. Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. Pediatr Radiol 2007; 37:544-8. [cited 31 times]


Page 19

83. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-8. [cited 157 times]

84. Behrens EM, Beukelman T, Cron RQ. Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [letter]. J Rheumatol 2007; 34:234. [cited 10 times]

85. Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. J Rheumatol 2006; 33:2330-6. [cited 28 times]

86. Beukelman T, Cron RQ. JIA-associated growth failure and exogenous growth hormone therapy. Pediatr Rheumatol Online J 2005; 3:99-108.

In press:

1. Stoll ML, Amin D, Powell KK, Poholek C, Strait RG, Aban I, Beukelman T, Young D, Cron RQ, Waite PD. Risk factors for heterotopic bone formation in the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol. [accepted 7 Feb 2018]

2. Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. [accepted 15 Feb 2018]

3. Caughey GE, Gabb GB, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of statin exposure with histologically-confirmed idiopathic inflammatory myositis: A population-based case control study. JAMA Inter Med. [accepted 6 May 2018]

4. Crayne CB, Beukelman T. Juvenile idiopathic arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am. [accepted 27 Apr 2018]

Submitted:

1. Azerf SP, Weiser P, Beukelman T, Feig DI, Cron RQ. Rituximab treatment for chronic Henoch-Schonlein Purpura.

2. Avant L, Tambralli A, Jester T, Beukelman T, Dimmitt RA, Cron RQ, Stoll ML. High dose infliximab for pediatric inflammatory bowel disease.

3. Beukelman T, Xie F, Baddley JW, Chen L, Horton DB, Mannion ML, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection associated with abatacept versus tumor necrosis factor inhibitors in the treatment of juvenile idiopathic arthritis.

4. Angeles-Han ST, Lo MS, Henderson LA, Lerman MA, Wallace C, Abramson L, Cooper A, Parsa MF, Zemel LS, Ronis T, Beukelman T, Weiss J, Cox E, Sen HN, Holland GN, Brunner HI, Lasky A, Rabinovich CE. Consensus treatment plans for juvenile idiopathic arthritis-associated uveitis and idiopathic anterior uveitis.

5. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis.

In preparation:


Page 20

Other publications:

1. Beukelman T, Curtis JR, Saag KG. Serious infections in childhood-onset systemic lupus erythematosus: Using administrative claims data to investigate disease outcomes [Editorial]. Arthritis Care Res 2017. [published online 19 Feb 2017]

2. Beukelman T, Cron RQ, Patkar NM, Saag KG, DeWitt EM, Lovell DJ, Ilowite NT, Kimura Y, Laxer RM, Martini A, Ruperto N, Rabinovich CE. Reply [Letter]. Arthritis Care Res 2011; 63:1355-6. [cited 3 times]

3. Lovell DJ, Henrickson M, DeWitt EM, Segerman J, Taylor J, Giannini EH, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Ilowite NT, Kimura Y, Stein LD, Vehe RK. Reply [Letter]. Arthritis Care Res 2011; 63:1353.

4. Tolleson-Rinehart S, Morgan DeWitt E, Massie S, Beukelman T, Froyum Roise A, Boggan J, Kautz J, Racine C, Olson M, Shores M, Belhorn T, Stein L, Stiles A, Pham V, Goolsby T (of the PEDS Group). Pharmacological Treatment of Juvenile Idiopathic Arthritis: A Pediatric Education for Drug Safety (PEDS) Continuing Education Module. http://pedscme.unc.edu. 1 May 2008.

Books

1. Cron RQ, Weiser P, Beukelman T. Juvenile idiopathic arthritis. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology: Principles and Practice, 5th Edition. London: Elsevier; 2018: .

2. Beukelman T, Brunner HI. Trial design, measurement, and analysis of clinical investigations. In: Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology, 7th Edition. Philadelphia: Elsevier; 2016: 54-77.

3. Cron RQ, Weiser P, Beukelman T. Juvenile idiopathic arthritis. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology: Principles and Practice, 4th Edition. London: Elsevier; 2013:637-47.

4. Beukelman T, Cron RQ, Hanson E. Ankylosing spondylitis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:50-1.

5. Beukelman T, Cron RQ. Dermatomyositis/Polymyositis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:262-3.

6. Beukelman T, Cron RQ, Hanson E. Diskitis. In: Schwartz MW, editor. The 5-Minute Pediatric Consult, 6th Edition. Philadelphia: Lippincott Williams & Wilkins; 2012:282-3.

In press: Published Abstracts

1. Horton DB, Xie F, Mannion ML, Ringold S, Correll CK, Dennos AC, Beukelman T. Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

2. Mannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos AC, Beukelman T. Biologic Switching Among JIA Patients: A Cohort Study in the


Page 21

Childhood Arthritis and Rheumatology Research Alliance Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

3. Ringold S, Xie F, Horton DB, Mannion ML, Correll CK, Dennos AC, Beukelman T. Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

4. Huang B, Morgan E, Chen C, Liu J, Adams M, Beukelman T, Brunner HI, Lovell DJ. Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

5. Foeldvari I, Beukelman T, Xie F. Assessing the Prevalence of Juvenile Systemic Sclerosis in Childhood Using Administrative Claims Data from the United States [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

6. Eloseily EMA, Minoia F, Beukelman T, Ravelli A, Cron RQ. The Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).

7. Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion ML, Saag KG, Curtis JR. The risk of malignancy associated with use of tumor necrosis factor inhibitors in childhood. Pharmacoepidemiol Drug Saf 2017;

8. Horton DB, Xie F, Chen L, Mannion ML, Strom BL, Curtis JC, Beukelman T. Oral glucocorticoids and incident diabetes mellitus and hypertension in children with chronic diseases. Pharmacoepidemiol Drug Saf 2017;

9. Beukelman T, Xie F, Chen L, Horton D, Lewis JD, Mamtani R, Mannion M, Saag KG, Zhang J, Curtis JR. Tumor necrosis factor inhibitors and the risk of malignancy in the treatment of juvenile idiopathic arthritis. Arthritis Rheumatol 2016; 68(suppl 10).

10. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection associated with initiation of abatacept versus TNF inhibitors in juvenile idiopathic arthritis. Arthritis Rheumatol 2016; 68(suppl 10).

11. Ringold S, Kimura Y, Schanberg LE, Natter MD, Xie F, Ilowite N, Jones J, Mieszkalski K, Beukelman T. Patterns of medication use in children with juvenile idiopathic arthritis: Results from the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Rheumatol 2016; 68(suppl 10).

12. Curtis J, Xie F, Saag K, Chen L, Beukelman T, Mannion M, Yun H. Changing patterns over time in opiate use in U.S. rheumatoid arthritis patients. Arthritis Rheumatol 2016; 68(suppl 10).

13. Xie F, Chen L, Yun H, Beukelman T, Curtis J. Ustekinumab, apremilast, TNFi and the risk for hospitalized infection in patients with psoriasis and psoriatic arthritis. Arthritis Rheumatol 2016; 68(suppl 10).

14. Horton DB, Xie F, Chen L, Mannion M, Strom BL, Curtis J, Beukelman T. Oral glucocorticoids and rates of incident diabetes mellitus and hypertension in children with juvenile idiopathic arthritis and attention deficit/hyperactivity disorder. Arthritis Rheumatol 2016; 68(suppl 10).


Page 22

15. Beukelman T, Kimura Y, Natter MD, Ilowite NT, Mieszkalski K, Burrell G, Best B, Bristow H, Carr S, Dennos A, Kaufmann R, Schanberg LE. Clinical characteristics of the initial patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Pediatr Rheumatol Online J 2016.

16. Beukelman T, Xie F, Mannion M, Chen L, Zhang J, Baddley J, Saag K, Curtis JR. The risk of hospitalized infection associated with new use of abatacept versus TNF inhibitors in juvenile idiopathic arthritis. Pharmacoepidemiol Drug Saf 2016;

17. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag K, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Rheumatol 2015; 67(suppl 10).

18. Gmuca S, Brandon T, Xiao R, Pagnini I, Wright TB, Beukelman T, Morgan-DeWitt E, Weiss PF. Pediatric enthesisit-related arthritis: Variation in disease characteristics and treatments among 5 large centers. Arthritis Rheumatol 2015; 67(suppl 10).

19. Mannion ML, Williams M, Ivankova N, McGwin G, Saag KG, Beukelman T. Qualitative assessment of patient important long-term outcomes in juvenile idiopathic arthritis. Arthritis Rheumatol 2015; 67(suppl 10).

20. Mannion ML, Pedro S, Beukelman T, Curtis JR, Michaud K. Comparison of JIA and RA patients in the National Data Bank for Rheumatic Diseases. Arthritis Rheumatol 2015; 67(suppl 10).

21. Gmuca S, Brandon T, Xiao R, Pagnini I, Wright TB, Beukelman T, Morgan-DeWitt E, Weiss PF. Phenotypic differences between HLA-B27 positive and negative children with enthesitis-related arthritis. Arthritis Rheumatol 2015; 67(suppl 10).

22. Zhang J, Curtis JR, Xie F, Mannion ML, Lewis JD, Clowse MEB, Saag KG, Bethard S, Biggio J, McGwin G, Beukelman T. Utilization of immune-suppressive medications during pregnancy among women with inflammatory arthritis or other autoimmune diseases. Arthritis Rheumatol 2015; 67(suppl 10).

23. Kimura Y, Beukelman T, Morgan-DeWitt E, Mieszkalski KL, Graham TB, Ibarra MF, Ilowite N, Klein-Gitelman MS, Onel K, Prahalad S, Punaro MG, Ringold S, Toib D, Van Mater H, Weiss PF, Schanberg L. Results from the Childhood Arthritis and Rheumatology Research Alliance systemic JIA consensus treatment plans pilot study. Arthritis Rheumatol 2015; 67(suppl 10).

24. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag K, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Pharmacoepidemiol Drug Saf 2015;

25. Beukelman T, Berntson L, Duffy CM, Guzman J, Kimura Y, Klotsche J, Magnusson B, Minden K, Nordal E, Santos MJ, Thomson W, Zilhao C, Hyrich KL. The initial treatment of systemic juvenile idiopathic arthritis: An international collaboration among 7 registries. Ann Rheum Dis 2015; 74(Suppl2):392-3.

26. Mannion M, Williams M, McGwin G, Saag K, Beukelman T. Qualitative assessment of important long-term outcomes in juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66 Suppl 11:S129.


Page 23

27. Trambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in pediatric lupus and other rheumatic diseases. Arthritis Rheumatol 2014; 66 Suppl 11:S568.

28. Kimura Y, Morgan-DeWitt E, Mieszkalski KL, Graham TB, Beukelman T, Ibarra MF, Ilowite NT, Klein-Gitelman MS, Onel K, Parhalad S, Punaro MG, Ringold S, Toib D, Van Mater H, Weiss PF, Schanberg L. Preliminary results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Cosensus Treatment Plan pilot study. Arthritis Rheumatol 2014; 66 Suppl 11:S1000-1.

29. Beukelman T, Carrasco R, Kimura Y, Schanberg L, Thomson W, Hyrich KL. The presentation and initial treatment of systemic juvenile idiopathic arthritis according to observational data from the United States and the United Kingdom. Arthritis Rheumatol 2014; 66 Suppl 11:S1001.

30. Hinze C, Foell D, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ. The role of serum S100A12 protein levels in disease flare after withdrawal of anti-tumor necrosis factor therapy in polyarticular forms of juvenile idiopathic arthritis. Arthritis Rheumatol 2014;66 Suppl 3:S19-20.

31. Lovell DJ, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Foell D, Huang B, Giannini EH. Understanding the use and biology of TNF therapy in JIA: clinical outcomes. Arthritis Rheumatol 2014;66 Suppl 3:S31-2.

32. Mor-Vaknin N, Rivas M, Legendre M, Ye CY, Johnson A, Huang B, Zhao L, Kimura Y, Spalding SJ, Morris P, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung LK, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ, Markovitz D. High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy. Arthritis Rheumatol 2014;66 Suppl 3:S65-6.

33. Hinze C, Foell D, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ. The role of serum S100A12 protein levels in maintaining inactive disease on anti-tumor necrosis factor therapy in polyarticular forms of juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66 Suppl 3:S99-S100.

34. Curtis JR, Yun H, Zhang J, Xie F, Chen L, Levitan E, Lewis J, Beukelman T, Saag KG, Navarro-Millan I. Comparing myocardial infarction risks associated with biologics of varying mechanisms of action among older rheumatoid arthritis patients. Arthritis Rheum 2013; 65 Suppl 10:S157.

35. Mannion ML, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of TNF inhibitors. Arthritis Rheum 2013; 65 Suppl 10:S336-7.

36. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley J, Curtis JR. Physician proclivity to use oral glucocorticoids among rheumatoid arthritis patients. Arthritis Rheum 2013; 65 Suppl 10:S449-50.


Page 24

37. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Schiff MH, Beukelman T, Ginsberg S. Use of oral and subcutaneous MTX in a commercially insured rheumatoid arthritis population. Arthritis Rheum 2013; 65 Suppl 10:S450.

38. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop LK, Baddley JW, Muntner PM, Curtis JR. Comparative safety of biological agents among rheumatoid arthritis patients. Arthritis Rheum 2013; 65 Suppl 10:S987.

39. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Muntner P, Curtis JR. Risk of subsequent infection among rheumatoid arthritis patients using biologics. Arthritis Rheum 2013; 65 Suppl 10:S1144.

40. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risks of herpes zoster among RA patients switching biologics in the U.S. Medicare program. Arthritis Rheum 2013; 65 Suppl 10:S1179-80.

41. Mannion M, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the U.S. and the influence of TNF inhibitors. Pharmacoepidemiol Drug Saf 2013; 22 Suppl 1:444.

42. Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E, Curtis JR. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. Pharmacoepidemiol Drug Saf 2013; 22 Suppl 1:288.

43. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K, Baddley J, Muntner P, Curtis JR. Comparative safety of biologic agents among Medicare rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf 2013; 22 Suppl 1:20.

44. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K. Comparative risks of recurrent hospitalized infection association with biologics in RA patients at high risk. Pharmacoepidemiol Drug Saf 2013; 22 Suppl 1:442.

45. Mannion M, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the Unites States and the influence of TNF inhibitors. Ann Rheum Dis 2013; 72(Suppl3):149.

46. Cron RQ, Tramballi A, Beukelman T, Weiser P, Atkinson TP, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. Ann Rheum Dis 2013; 72(Suppl3):744.

47. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Munter P, Curtis JR. Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. Ann Rheum Dis 2013; 72(Suppl3):553.

48. Beukelman T, Xie F, Baddley J, Chen L, Delzell E, Grijalva C, Mannion ML, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2012; 64 Suppl 10:S329.

49. Weiss JE, Morgan DeWitt EM, Beukelman T, Schanberg LE, Schneider R, Kimura Y. Choice of systemic JIA treatment among Childhood Arthritis and Rheumatology Research Alliance (CARRA) rheumatologists. Arthritis Rheum 2012; 64 Suppl 10:S492.

50. Luca N, Burnett H, Ungar W, Beukelman T, Feldman BM, Schwartz G, Bayoumi A. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64 Suppl 10:S501.


Page 25

51. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. Arthritis Rheum 2012; 64 Suppl 10:S401.

52. Cron RQ, Zhang M, Bemrich-Stolz CJ, Beukelman T. Rapid and effective response to immunosuppression in treating macrophage activation syndrome associated with a heterozygous dominant negative mutation in RAB27a leading to decreased cytolytic activity. Arthritis Rheum 2012; 64 Suppl 10:S1125.

53. Bingham CA, Darbie LM, Marsolo K, Weiss JE, Ardoin SP, Laxer RM, Lovell DJ, Passo MH, Vora S, Gottlieb BS, Beukelman T, Griffin N, Stock JA, Miller ML, Onel K, Ronis T, Margolis P, Morgan DeWitt EM. Improving delivery of care for JIA across a multi-center network using a shared data registry and quality improvement science: The Pediatric Rheumatology Care and Outcomes Improvement Network. Arthritis Rheum 2012; 64 Suppl 10:S1101.

54. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Pharmacoepidemiol Drug Saf 2012; 21 Suppl 3:S45.

55. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a national arthritis cohort with medicare administrative claims data. Pharmacoepidemiol Drug Saf 2012; 21 Suppl 3:S46.

56. Beukelman T, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. DMARD use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Ann Rheum Dis 2012; 71(Suppl3):438.

57. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva C, Patkar N, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71 (Suppl3):270.

58. Beukelman T, Bingham CA, Gottlieb BS, Griffin N, Laxer R, Marsolo K, Passo MH, Lannon C, Margolis P, DeWitt EM. Increasing quality of JIA treatment: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN). Ann Rheum Dis 2012; 71(Suppl3):706.

59. Beukelman T, Ringold S, Davis T, Morgan DeWitt E, Pelajo CF, Weiss P, Kimura Y. Utilization of biologic and non-biologic disease modifying anti-rheumatic drugs in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Rheum 2011; 63 Suppl 10:S104.

60. Weiss P, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis-specific pain across juvenile idiopathic arthritis (JIA) categories: Preliminary analyses from the CARRA-net Registry. Arthritis Rheum 2011; 63 Suppl 10:S105.

61. Morgan DeWitt E, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Ilowite NT, Wallace CA, Kimura Y. Development of consensus treatment plants for new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2011; 63 Suppl 10:S106.

62. Miller M, Beukelman T, Lales G, McKenna S, Ruprecht J, Curran ML, Klein-Gitelman MS. Application and examination of the key clinical parameters from the 2011 ACR


Page 26

recommendations for the treatment of JIA using electronic medical record-derived data from a clinical cohort. Arthritis Rheum 2011; 63 Suppl 10:S98.

63. Morgan DeWitt E, Beukelman T, Gottlieb BS, Griffin N, Kimura Y, Barnes I, Passo MH. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. Arthritis Rheum 2011; 63 Suppl 10:S803-4.

64. Grijalva C, Chen L, Delzell E, Baddley J, Beukelman T, Winthrop K, Griffin M, Herrinton, Liu L, Nourjah P, Patkar NM, Solomon DH, Lewis J, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalization for infection in patients with autoimmune diseases. Arthritis Rheum 2011; 63 Suppl 10:S316.

65. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment [abstract]. Pharmacoepidemiol Drug Saf 2011; 20 Suppl 1:S13.

66. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Griffin MR, Herrinton L, Liu L, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Winthrop KL, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalized bacterial infections in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2011; 20 Suppl 1:S182.

67. Curtis J, Xie F, Chen L, Beukelman T, Saag K, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents [abstract]. Ann Rheum Dis 2011.

68. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Delzell E, Kim H, Saag KG, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S871

69. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S879-80.

70. Beukelman T, Xie F, Curtis JR. Usage of TNFα inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S100-1.

71. Curtis JR, Xie F, Chen L, Baddley J, Beukelman T, Saag KG, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S300-1

72. Beukelman T, Xie F, Chen L, Baddley J, Delzell E, Grijalva, Patkar NM, Saag KG, Winthrop K, Curtis JR. Characteristics of cases of PML among patients with selected rheumatic and autoimmune diseases [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S300.

73. Winthrop KL, Baddley J, Chen L, Liu L, Grijalva CG, Patkar NM, Xie F, Delzell E, Beukelman T, Herrinton LJ, Saag KG, Curtis JR. Rates of tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients who use anti-tumor necrosis factor alpha therapy; from the SAfety of Biologic ThERapy (SABER) study [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S170.


Page 27

74. Record JL, Beukelman T, Cron RQ. High prevalence of inflammatory myositis in patients with pediatric systemic lupus erythematosus in a US southeastern state [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S700.

75. Sharpe T, Good J, Beukelman T, Waite PD, Cron RQ. Benefit of intra-articular corticosteroid injections by oral and maxillofacial surgery treating temporomandibular joint arthritis in children with juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2010; 62 Suppl 10:S90.

76. Cron RQ, Beukelman T, Bemrich-Stolz C, Watts RG. IL-1 antagonsim for treatment of macrophage activation syndrome [abstract]. Pediatr Blood Cancer 2011; 56:701.

77. Cron RQ, Genin A, Brunner M, Scalzi LV, Mishra N, Beukelman T, Mehta J. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis [abstract]. J Immunol 2010; 184:135.4.

78. Beukelman T, Delzell E, Saag KG. The risk of serious infection in juvenile idiopathic arthritis [abstract]. Clin Transl Sci 2010; 3:S8.

79. Morgan Dewitt E, Passo M, Kimura Y, Beukelman T, Gottlieb B, Margolis P. Pediatric rheumatology improvement network for clinical excellence and safety—PRINCES [abstract]. Arthritis Rheum 2009; 60 Suppl 10:S705.

80. Beukelman T, Saag KG, Curtis JR, Nair R, Kilgore ML, Pisu M. The cost-effectiveness of a multi-modal intervention for the prevention of glucocorticoid-induced osteoporosis [abstract]. Arthritis Rheum 2008; 58 Suppl 9:S739.

81. Cron RQ, Beukelman T, Reed AB, Behrens EM. IL-1 antagonism for treatment of macrophage activation syndrome [abstract]. Arthritis Rheum 2008; 58 Suppl 9:S247-8.

82. Beukelman T, Guevara J, Albert DA. Outcomes in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: Results of a decision analysis model [abstract]. Arthritis Rheum 2007; 56 Suppl 9:S136.

83. Beukelman T, Guevara J, Albert DA, Sherry DD, Burnham J. Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada [abstract]. Arthritis Rheum 2006; 54:4030.

84. Behrens E, Beukelman T, Gallo L, Spangler J, Rosenkrantz M, Arkachaisri T, et al. Pennsylvania systemic onset juvenile arthritis registry (PASOJAR): presenting characteristics and demographic data of a large cohort [abstract]. Arthritis Rheum 2006; 54:4057.

85. Behrens E, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in systemic juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2006; 54 Suppl 9:S695.

86. Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intra-articular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2005; 52 Suppl 9:S85.

87. Behrens E, Beukelman T, Tustin N, Cron RQ, Pessler F. Secondary hemophagocytic lymphohistiocytosis: Is there a role for Interleukin-1 blockade? [abstract]. Clin Immunol 2005; 116:298-9.

Poster Exhibits

1. Horton DB, Xie F, Mannion ML, Ringold S, Correll CK, Dennos AC, Beukelman T. Factors Related to Sustained Discontinuation of Medications for Well-


Page 28

Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry. American College of Rheumatology Annual Scientific Meeting, 2017.

2. Mannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos AC, Beukelman T. Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. American College of Rheumatology Annual Scientific Meeting, 2017.

3. Ringold S, Xie F, Horton DB, Mannion ML, Correll CK, Dennos AC, Beukelman T. Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry. American College of Rheumatology Annual Scientific Meeting, 2017.

4. Huang B, Morgan E, Chen C, Liu J, Adams M, Beukelman T, Brunner HI, Lovell DJ. Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data. American College of Rheumatology Annual Scientific Meeting, 2017.

5. Foeldvari I, Beukelman T, Xie F. Assessing the Prevalence of Juvenile Systemic Sclerosis in Childhood Using Administrative Claims Data from the United States. American College of Rheumatology Annual Scientific Meeting, 2017.

6. Ringold S, Xie F, Kimura K, Schanberg LE, Beukelman T. Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry. American College of Rheumatology Pediatric Rheumatology Symposium (PRSYM), 2017.

7. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection associated with initiation of abatacept versus TNF inhibitors in juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2016.

8. Ringold S, Kimura Y, Schanberg LE, Natter MD, Xie F, Ilowite N, Jones J, Mieszkalski K, Beukelman T. Patterns of medication use in children with juvenile idiopathic arthritis: Results from the Childhood Arthritis and Rheumatology Research Alliance Registry. American College of Rheumatology Annual Scientific Meeting, 2016.

9. Curtis J, Xie F, Saag K, Chen L, Beukelman T, Mannion M, Yun H. Changing patterns over time in opiate use in U.S. rheumatoid arthritis patients. American College of Rheumatology Annual Scientific Meeting, 2016.

10. Xie F, Chen L, Yun H, Beukelman T, Curtis J. Ustekinumab, apremilast, TNFi and the risk for hospitalized infection in patients with psoriasis and psoriatic arthritis. American College of Rheumatology Annual Scientific Meeting, 2016.

11. Horton DB, Xie F, Chen L, Mannion M, Strom BL, Curtis J, Beukelman T. Oral glucocorticoids and rates of incident diabetes mellitus and hypertension in children with juvenile idiopathic arthritis and attention deficit/hyperactivity disorder. American College of Rheumatology Annual Scientific Meeting, 2016.

12. Beukelman T, Kimura Y, Natter MD, Ilowite NT, Mieszkalski K, Burrell G, Best B, Bristow H, Carr S, Dennos A, Kaufmann R, Schanberg LE. Clinical characteristics of the initial patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Pediatric Rheumatology European Socitey Congress, 2016.


Page 29

13. Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag K, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2015.

14. Gmuca S, Brandon T, Xiao R, Pagnini I, Wright TB, Beukelman T, Morgan-DeWitt E, Weiss PF. Pediatric enthesisit-related arthritis: Variation in disease characteristics and treatments among 5 large centers. American College of Rheumatology Annual Scientific Meeting, 2015.

15. Mannion ML, Williams M, Ivankova N, McGwin G, Saag KG, Beukelman T. Qualitative assessment of patient important long-term outcomes in juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2015.

16. Mannion ML, Pedro S, Beukelman T, Curtis JR, Michaud K. Comparison of JIA and RA patients in the National Data Bank for Rheumatic Diseases. American College of Rheumatology Annual Scientific Meeting, 2015.

17. Gmuca S, Brandon T, Xiao R, Pagnini I, Wright TB, Beukelman T, Morgan-DeWitt E, Weiss PF. Phenotypic differences between HLA-B27 positive and negative children with enthesitis-related arthritis. American College of Rheumatology Annual Scientific Meeting, 2015.

18. Zhang J, Curtis JR, Xie F, Mannion ML, Lewis JD, Clowse MEB, Saag KG, Bethard S, Biggio J, McGwin G, Beukelman T. Utilization of immune-suppressive medications during pregnancy among women with inflammatory arthritis or other autoimmune diseases. American College of Rheumatology Annual Scientific Meeting, 2015.

19. Beukelman T, Berntson L, Duffy CM, Guzman J, Kimura Y, Klotsche J, Magnusson B, Minden K, Nordal E, Santos MJ, Thomson W, Zilhao C, Hyrich KL. The initial treatment of systemic juvenile idiopathic arthritis: An international collaboration among 7 registries. Annual European Congress of Rheumatology, 2015.

20. Mannion M, Williams M, McGwin G, Saag K, Beukelman T. Qualitative assessment of important long-term outcomes in juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2014.

21. Trambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in pediatric lupus and other rheumatic diseases. American College of Rheumatology Annual Scientific Meeting, 2014.

22. Kimura Y, Morgan-DeWitt E, Mieszkalski KL, Graham TB, Beukelman T, Ibarra MF, Ilowite NT, Klein-Gitelman MS, Onel K, Parhalad S, Punaro MG, Ringold S, Toib D, Van Mater H, Weiss PF, Schanberg L. Preliminary results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Cosensus Treatment Plan pilot study. American College of Rheumatology Annual Scientific Meeting, 2014.

23. Beukelman T, Carrasco R, Kimura Y, Schanberg L, Thomson W, Hyrich KL. The presentation and initial treatment of systemic juvenile idiopathic arthritis according to observational data from the United States and the United Kingdom. American College of Rheumatology Annual Scientific Meeting, 2014.

24. Hinze C, Foell D, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ. The role of serum S100A12 protein


Page 30

levels in disease flare after withdrawal of anti-tumor necrosis factor therapy in polyarticular forms of juvenile idiopathic arthritis. Pediatric Rheumatology Symposium, 2014.

25. Lovell DJ, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb BS, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Foell D, Huang B, Giannini EH. Understanding the use and biology of TNF therapy in JIA: clinical outcomes. Pediatric Rheumatology Symposium, 2014.

26. Mor-Vaknin N, Rivas M, Legendre M, Ye CY, Johnson A, Huang B, Zhao L, Kimura Y, Spalding SJ, Morris P, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung LK, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ, Markovitz D. High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy. Pediatric Rheumatology Symposium, 2014.

27. Hinze C, Foell D, Johnson A, Kimura Y, Spalding SJ, Morris PW, Gottlieb B, Onel K, Olson JC, Edelheit B, Shishov M, Jung L, Cassidy E, Prahalad S, Passo MH, Beukelman T, Mehta J, Schmidt KM, Giannini EH, Lovell DJ. The role of serum S100A12 protein levels in maintaining inactive disease on anti-tumor necrosis factor therapy in polyarticular forms of juvenile idiopathic arthritis. Pediatric Rheumatology Symposium, 2014.

28. Curtis JR, Yun H, Zhang J, Xie F, Chen L, Levitan E, Lewis J, Beukelman T, Saag KG, Navarro-Millan I. Comparing myocardial infarction risks associated with biologics of varying mechanisms of action among older rheumatoid arthritis patients. American College of Rheumatology Annual Scientific Meeting, 2013.

29. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley J, Curtis JR. Physician proclivity to use oral glucocorticoids among rheumatoid arthritis patients. American College of Rheumatology Annual Scientific Meeting, 2013.

30. Curtis JR, Xie F, Zhang J, Chen L, Yun H, Schiff MH, Beukelman T, Ginsberg S. Use of oral and subcutaneous MTX in a commercially insured rheumatoid arthritis population. American College of Rheumatology Annual Scientific Meeting, 2013.

31. Yun H, Xie F, Delzell ES, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop LK, Baddley JW, Muntner PM, Curtis JR. Comparative safety of biological agents among rheumatoid arthritis patients. American College of Rheumatology Annual Scientific Meeting, 2013.

32. Mannion M, Xie F, Curtis JR, Beukelman T. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the U.S. and the influence of TNF inhibitors. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.

33. Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E, Curtis JR. Methods to link a U.S. arthritis chohrt with Medicare administrative claims data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.

34. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop K. Comparative risks of recurrent hospitalized infection association with biologics in RA patients at high risk. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2013.


Page 31

35. Cron RQ, Tramballi A, Beukelman T, Weiser P, Atkinson TP, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. Annual European Congress of Rheumatology, 2013.

36. Yun H, Xie F, Delzell E, Chen L, Levitan E, Lewis J, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Munter P, Curtis JR. Comparative risks for serious infections associated with biologics in high risk rheumatoid arthritis patients. Annual European Congress of Rheumatology, 2013.

37. Luca N, Burnett H, Ungar W, Beukelman T, Feldman BM, Schwartz G, Bayoumi A. Cost-effectiveness analysis of early biologic treatment in polyarticular juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2012.

38. Weiss JE, Morgan DeWitt EM, Beukelman T, Schanberg LE, Schneider R, Kimura Y. Choice of systemic JIA treatment among Childhood Arthritis and Rheumatology Research Alliance (CARRA) rheumatologists. American College of Rheumatology Annual Scientific Meeting, 2012.

39. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a U.S. arthritis cohort with Medicare administrative claims data. American College of Rheumatology Annual Scientific Meeting, 2012.

40. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2012.

41. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG, Delzell E. Methods to link a national arthritis cohort with medicare administrative claims data. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2012.

42. Beukelman T, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. DMARD use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. Annual European Congress of Rheumatology, 2012.

43. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva C, Patkar N, Saag KG, Curtis JR. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Annual European Congress of Rheumatology, 2012.

44. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. University of Alabama at Birmingham Center for Clinical and Translational Science Third Annual Scientific Symposium, 2011.

45. Beukelman T, Ringold S, Davis T, Morgan DeWitt E, Pelajo CF, Weiss P, Kimura Y. Utilization of biologic and non-biologic disease modifying anti-rheumatic drugs in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. American College of Rheumatology Annual Scientific Meeting, 2011.

46. Weiss P, Beukelman T, Schanberg LE, Kimura Y, Colbert RA. Enthesitis is a significant predictor of decreased quality of life, function, and arthritis-specific pain across juvenile idiopathic arthritis (JIA) categories: Preliminary analyses from the CARRA-net Registry. American College of Rheumatology Annual Scientific Meeting, 2011.

47. Morgan DeWitt E, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Ilowite NT, Wallace CA, Kimura Y. Development of consensus treatment plants for


Page 32

new-onset systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2011.

48. Miller M, Beukelman T, Lales G, McKenna S, Ruprecht J, Curran ML, Klein-Gitelman MS. Application and examination of the key clinical parameters from the 2011 ACR recommendations for the treatment of JIA using electronic medical record-derived data from a clinical cohort. American College of Rheumatology Annual Scientific Meeting, 2011.

49. Morgan DeWitt E, Beukelman T, Gottlieb BS, Griffin N, Kimura Y, Barnes I, Passo MH. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. American College of Rheumatology Annual Scientific Meeting, 2011.

50. Baddley JW, Winthrop KL, Grijalva CG, Chen L, Xie F, Delzell E, Beukelman T, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Saag KG, Curtis JR. Risk of non-mycobacterial opportunistic infections in new users of TNF inhibitor therapy: Results of the Safety Assessment of Biological Therapy study. Infectious Diseases Society of America Annual Meeting, 2011.

51. Baddley JW, Winthrop KL, Patkar NM, Delzell E, Xie F, Chen L, Beukelman T, Curtis JR. Incidence and risk factors for cryptococcosis in older Americans. Infectious Diseases Society of America Annual Meeting, 2011.

52. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Griffin MR, Herrinton L, Liu L, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Winthrop KL, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalized bacterial infections in patients with rheumatoid arthritis. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 2011.

53. Ringold S, Beukelman T, Morgan DeWitt E, Natter M, Nigrovic PA, Kimura Y. Disease characteristics and medications use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): Preliminary analyses from the CARRAnet registry. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.

54. Morgan DeWitt E, Beukelman T, Gottlieb BS, Griffin N, Kimura Y, McNiff K, Passo M. Measuring quality of care in juvenile idiopathic arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.

55. Morgan DeWitt E, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll M, Wallace CA, Kimura Y. Development of consensus best treatment plans for new-onset systemic juvenile idiopathic arthritis. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.

56. Cron RQ, Fain E, Atkinson G, Weiser P, Beukelman T. Temporomandibular joint arthritis in patients with non-JIA childhood arthritis. American College of Rheumatology Pediatric Rheumatology Symposium, 2011.

57. Curtis J, Xie F, Chen L, Beukelman T, Saag K, Winthrop K, Delzell E. The comparative incidence of serious infections among rheumatoid arthritis patients who switch biologic agents. Annual European Congress of Rheumatology, 2011.

58. Beukelman T, Xie F, Curtis JR. Usage of TNFα inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database. American College of Rheumatology Annual Scientific Meeting, 2010.


Page 33

59. Winthrop KL, Baddley J, Chen L, Liu L, Grijalva CG, Patkar NM, Xie F, Delzell E, Beukelman T, Herrinton LJ, Saag KG, Curtis JR. Rates of tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients who use anti-tumor necrosis factor alpha therapy; from the SAfety of Biologic ThERapy (SABER) study. American College of Rheumatology Annual Scientific Meeting, 2010.

60. Record J, Beukelman T, Cron RQ. High prevalence of inflammatory myositis in patients with pediatric systemic lupus erythematosus in a US southeastern state. American College of Rheumatology Annual Scientific Meeting, 2010.

61. Sharpe T, Good J, Beukelman T, Waite PD, Cron RQ. Benefit of intra-articular corticosteroid injections by oral and maxillofacial surgery treating temporomandibular joint arthritis in children with juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2010.

62. Cron RQ, Beukelman T, Bemrich-Stolz C, Watts RG. IL-1 antagonsim for treatment of macrophage activation syndrome. Histiocyte Society Annual Scientific Meeting, 2010.

63. Cron RQ, Genin A, Brunner M, Scalzi LV, Mishra N, Beukelman T, Mehta J. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased CD154 transcription, increased NFAT activity, and glomerulonephritis. American Association of Immunologists Annual Meeting, 2010.

64. Beukelman T, Saag KG, Curtis JR, Nair R, Kilgore ML, Pisu M. The Cost-Effectiveness of a Multi-modal Intervention for the Prevention of Glucocorticoid-Induced Osteoporosis. American College of Rheumatology Annual Scientific Meeting, 2008.

65. Cron RQ, Beukelman T, Reed AB, Behrens EM. IL-1 antagonism for treatment of macrophage activation syndrome. American College of Rheumatology Annual Scientific Meeting, 2008.

66. Donnithorne K, Cron RQ, Beukelman T. Treatment with tumor necrosis factor alpha inhibitors in early versus established juvenile idiopathic arthritis. UAB Medical Student Research Day, 2008.

67. Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. American College of Rheumatology Keystone Pediatric Rheumatology Symposium, 2008.

68. Mehta J, Genin A, Brunner M, Beukelman T, Scalzi LV, Mishra N, Cron RQ. Prolonged CD154 expression in pediatric lupus CD4 T cells correlates with increased NFAT activity, NFAT c1 levels, and glomerulonephritis. American College of Rheumatology Keystone Pediatric Rheumatology Symposium, 2008. [oral presentation]

69. Beukelman T, Guevara J, Albert DA. Outcomes in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: Results of a decision analysis model. American College of Rheumatology Annual Scientific Meeting, 2007.

70. Beukelman T, Guevara J, Albert DA, Sherry DD, Burnham J. Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada. American College of Rheumatology Annual Scientific Meeting, 2006. [oral presentation]

71. Behrens E, Beukelman T, Gallo L, Spangler J, Rosenkrantz M, Arkachaisri T, et al. Pennsylvania systemic onset juvenile arthritis registry (PASOJAR): presenting characteristics and demographic data of a large cohort. American College of Rheumatology Annual Scientific Meeting, 2006.


Page 34

72. Behrens E, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in systemic juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2006.

73. Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intra-articular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. American College of Rheumatology Annual Scientific Meeting, 2005.

74. Behrens E, Beukelman T, Tustin N, Cron RQ, Pessler F. Secondary hemophagocytic lymphohistiocytosis: Is there a role for Interleukin-1 blockade? Clinical Immunology Society Primary Immunodeficiency Diseases Consortium Conference, 2005.

Oral Presentations Scientific papers presented at national and international meetings (international in bold):

1. “The risk of malignancy associated with use of tumor necrosis factor inhibitors in childhood”. Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 2017.

2. “Oral glucocorticoids and incident diabetes mellitus and hypertension in children with chronic diseases”. Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 2017. [senior author]

3. “Tumor necrosis factor inhibitors and the risk of malignancy in the treatment of juvenile idiopathic arthritis”. Plenary Abstract Session, American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2016.

4. “The risk of hospitalized infection associated with new use of abatacept versus TNF inhibitors in juvenile idiopathic arthritis”, Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 2016.

5. “The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis”, Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 2015.

6. “Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of TNF inhibitors”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, San Diego, CA, October 2013. [senior author]

7. “Recent trends in medication usage for the treatment of juvenile idiopathic arthritis in the Unites States and the influence of TNF inhibitors”, Abstract Session, Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

8. “Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2012.

9. “Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment”, Concurrent Abstract Session, International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, August 2011.

10. “Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data”, Plenary


Page 35

Abstract Session, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.

11. “2010 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis”, Clinical Symposium, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.

12. “Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, November 2010.

13. “Characterization of the treatment of juvenile idiopathic oligoarthritis by pediatric rheumatologists in the United States and Canada”, Concurrent Abstract Session, American College of Rheumatology Annual Scientific Meeting, Washington, D.C., November 2006.

Scientific papers presented at local and regional meetings: None Invited workshops: None Invited lectures at local and regional courses and meetings (international in bold):

1. “Investigating Adverse Effects of Biologic Agents”. Keynote Speaker, University of Pennsylvania Research Trainee Day, Philadelphia, PA, June 2017.

2. “The Role of Registries in the Future of Clinical Research”. Cincinnati Children’s Hospital Rheumatology Lecture, Cincinnati, OH, April 2016.

3. “Juvenile Idiopathic Arthritis”. Children’s of Alabama Springing into Rheumatology Mini-Conference, Birmingham, AL, March 2016.

4. “Investigating the Adverse Effects of Therapy of Uncommon Conditions”. UAB Health Services, Outcomes, and Effectiveness Research Methods Seminar, Birmingham, AL, December 2013.

5. “Usage and Safety of TNF Inhibitors in the Treatment of Juvenile Idiopathic Arthritis”. ACR/EULAR Exchange Program, Charité-University Medicine Berlin, Berlin, Germany, June 2013.

6. “Usage and Safety of TNF Inhibitors in the Treatment of Juvenile Idiopathic Arthritis”. ACR/EULAR Exchange Program, Karolinska Institute, Stockholm, Sweden, June 2013.

7. “Malignancy and Juvenile Idiopathic Arthritis: What is the Risk?”. University of Toronto/Hospital for Sick Children Pediatric Rheumatology Meeting, Toronto, Canada, September 2011.

8. “The Risk of Serious Infection and Malignancy in Juvenile Idiopathic Arthritis and Its Treatment”. AHRQ Centers for Education and Research on Therapeutics Scientific Conference, December 2010.

9. “The Risk of Infection and Malignancy in Juvenile Idiopathic Arthritis: Investigating the Incidence of Adverse Events Using Medicaid Administrative Claims Data”. University of Alabama at Birmingham Center for Clinical and Translational Science Second Annual Scientific Symposium, November 2010.

10. “Laboratory Testing in Pediatric Rheumatic Disease”, Educational Update for Pediatric Allergy, Immunology, and Rheumatology, Children’s Hospital of Alabama, February 2009.


Page 36

11. “Intra-articular Glucocorticoid Injections in the Treatment of Juvenile Idiopathic Arthritis”, The 53rd Annual Lowe Conference on Rheumatic Disease, Nauvoo, AL, October 2008.

12. “Medication Update”, Arthritis Foundation Juvenile Arthritis Family Day, Philadelphia, April, 2006.

13. “A Pediatric Rheumatologist’s View of Chronic Interstitial Lung Disease, Pulmonary Hypertension, and Pulmonary Capillaritis”, Pediatric Rheumatology Grand Rounds, The Children’s Hospital of Philadelphia, September, 2005.

14. “Immunosuppression and Infection in Rheumatic Disease”, Pediatric Rheumatology Grand Rounds, The Children’s Hospital of Philadelphia, April, 2005.

15. “The Hemophagocytic Syndrome”, Pediatric Rheumatology Grand Rounds, The Children’s Hospital of Philadelphia, December, 2004.

16. “Juvenile Fibromyalgia”, Chairman’s Rounds, Cincinnati Children’s Hospital Medical Center, August, 2003.

Lay Press [Convering the published manuscript: Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion ML, Saag KG, Curtis JR. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. [published online 9 Feb 2018]]

1. Walsh, N. Cancer risk stable in kids on anti-TNFs—but background risks higher than in the general population. MedPage Today 2018 Feb 20. https://www.medpagetoday.com/rheumatology/arthritis/71268

2. Laday, J. TNF inhibitor use does not exacerbate malignancy risk in children with rheumatic disease. Healio Rheumatology 2018 Feb 22. https://www.healio.com/rheumatology/juvenile-arthritis/news/online/%7Bb009b5c6-aed8-4679-ba2b-8e5d0d5a6232%7D/tnf-inhibitor-use-does-not-exacerbate-malignancy-risk-in-children-with-rheumatic-disease

3. Rothbard, G. TNF inhibitor therapy unlikely to affect malignancy risk in children. Rheumatology Advisor 2018 Feb 26. https://www.rheumatologyadvisor.com/pediatric-rheumatology/tumor-necrosis-factors-unlikely-to-affect-malignancy-risk-in-children-with-jia/article/746565/

4. Buckley, R. TNF inhibitors may not be linked to cancer risk in kids. The Rheumatologist 2018 Mar 1. http://www.the-rheumatologist.org/article/tnf-inhibitors-may-not-linked-cancer-risk-kids/

[Covering the scientific meeting abstract: Beukelman T, Xie F, Chen L, Horton D, Lewis JD, Mamtani R, Mannion M, Saag KG, Zhang J, Curtis JR. Tumor necrosis factor inhibitors and the risk of malignancy in the treatment of juvenile idiopathic arthritis. Arthritis Rheumatol 2016; 68(suppl 10).]

1. Walsh, N. Reassuring cancer data with JIA Tx: No apparent increase in risk with anti-TNF treatment. MedPage Today 2016 Nov 16. http://www.medpagetoday.com/meetingcoverage/acr/61505 http://www.medpagetoday.com/video/meetingcoverage/acr/acr-video-conference-reporter-2016/132/2038

https://www.medpagetoday.com/rheumatology/arthritis/71268

https://www.healio.com/rheumatology/juvenile-arthritis/news/online/%7Bb009b5c6-aed8-4679-ba2b-8e5d0d5a6232%7D/tnf-inhibitor-use-does-not-exacerbate-malignancy-risk-in-children-with-rheumatic-disease



https://www.rheumatologyadvisor.com/pediatric-rheumatology/tumor-necrosis-factors-unlikely-to-affect-malignancy-risk-in-children-with-jia/article/746565/

https://www.rheumatologyadvisor.com/pediatric-rheumatology/tumor-necrosis-factors-unlikely-to-affect-malignancy-risk-in-children-with-jia/article/746565/

http://www.the-rheumatologist.org/article/tnf-inhibitors-may-not-linked-cancer-risk-kids/

http://www.medpagetoday.com/meetingcoverage/acr/61505


Page 37

2. Sullivan, MG. TNF inhibitors don’t bood cancer risk in JIA [video interview]. Rheumatology News 2016 Nov 17. http://www.mdedge.com/rheumatologynews/article/118346/pediatrics/video-tnf-inhibitors-dont-boost-cancer-risk-jia

3. Abrams Kaplan, D. Malignancies in JIA not linked to TNFi treatment. Rheumatology Network 2016 Nov 16. http://www.rheumatologynetwork.com/ACR-RN-2016/malignancies-jia-not-linked-tnfi-treatment

4. Johnson, K. Cancer risk in juvenile arthritis no higher with TNF blocker. Medscape 2016 Nov 18. http://www.medscape.com/viewarticle/872091

[Covering the published manuscript: Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, Zhang J, Curtis JR. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2016 Sep 22;18:210.]

1. Offit, W. Compared with MTX, TNF inhibitor monotherapy, combination therapy did not increase infection risk in JIA. Healio Rheumatology 2016 Sept 30. http://www.healio.com/rheumatology/juvenile-arthritis/news/online/%7Bc5e4eaab-0dfe-4d60-815f-45ab1721f254%7D/compared-with-mtx-tnf-inhibitor-monotherapy-combination-therapy-did-not-increase-infection-risk-in-jia

[Covering the published manuscript: Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:2773-80.]

1. Walsh, N. Infection risk high in juvenile arthritis. Medpage today 2012 May 1. http://www.medpagetoday.com/Rheumatology/Arthritis/32434

[Covering the published manuscript: Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:1263-7.]

1. Carollo, K. Juvenile idiopathic arthritis may raise kids’ cancer risk. ABCnews.com 2012 Feb 13. http://abcnews.go.com/Health/juvenile-idiopathic-arthritis-linked-elevated-cancer-risk-study/story?id=15559238

2. Hansen, J. Medical detectives: UAB researchers, colleagues probe the case of juvenile arthritis drug side effect. The Birmingham News 2012 Feb 16: E1,4. http://www.al.com/living/index.ssf/2012/02/uab_researcher_colleagues_prob.html

3. Bankhead, C. Arthritis in kids may raise cancer risk. Medpage today 2012 Feb 13. http://www.medpagetoday.com/Rheumatology/Arthritis/31142

4. Boyles, S. Cancer risk higher for kids with arthritis: Medications used to treat condition likely not to blame. WebMD 2012 Feb 13. http://www.webmd.com/rheumatoid-arthritis/news/20120213/cancer-risk-higher-kids-with-arthritis

5. Picard, A. Good news/bad news for kids with juvenile arthritis. The Globe and Mail 2012 Feb 13. http://m.theglobeandmail.com/life/health/new-health/conditions/cancer/other-

http://www.mdedge.com/rheumatologynews/article/118346/pediatrics/video-tnf-inhibitors-dont-boost-cancer-risk-jia

http://www.mdedge.com/rheumatologynews/article/118346/pediatrics/video-tnf-inhibitors-dont-boost-cancer-risk-jia

http://www.rheumatologynetwork.com/ACR-RN-2016/malignancies-jia-not-linked-tnfi-treatment

http://www.rheumatologynetwork.com/ACR-RN-2016/malignancies-jia-not-linked-tnfi-treatment

http://www.medscape.com/viewarticle/872091

http://www.healio.com/rheumatology/juvenile-arthritis/news/online/%7Bc5e4eaab-0dfe-4d60-815f-45ab1721f254%7D/compared-with-mtx-tnf-inhibitor-monotherapy-combination-therapy-did-not-increase-infection-risk-in-jia



http://www.medpagetoday.com/Rheumatology/Arthritis/32434


Page 38

cancers/good-newsbad-news-for-kids-with-juvenile-arthritis /article2336468/ ?service=mobile

6. Williams, L. Juvenile arthritis patient risk for cancer highlighted. MedWire News 2012 Feb 13. http://www.medwire-news.md/46/97511/Oncology/ Juvenile_arthritis_patient _risk_for_cancer_highlighted.html

7. Mitchell, M. Juvenile arthritis and cancer risk, what parents should know. EmaxHealth 2012 Feb 13. http://www.emaxhealth.com/1275/juvenile-arthritis-and-cancer-risk-what-parents-should-know

8. Davis, JL. More evidence reveals JIA treatment isn’t cause of cancer risk. Arthritis Today 2012 Feb 13. http://www.arthritistoday.org/news/juvenile-arthritis-treatment-cancer-risk179.php

9. Harding, A. TNF drugs for juvenile arthritis don’t boost malignancies. Reuters Health 2012 March 16.

10. Moon, M. Cancer rate higher in JIA, regardless of therapy. Rheumatology News 2012 March:11.

[Covering the published manuscript: Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res 2011; 63:465-82.]

1. Walsh, N. New JIA treatment recommendations published. Medpage Today 2011 April 1. http://www.medpagetoday.com/Rheumatology/Arthritis/25662

2. Kelly, J. First ACR advice for juvenile idiopathic arthritis treatment. Medscape News 2011 April 4. http://www.medscape.com/viewarticle/740148

3. Rothman Schonfeld, A. JIA guidelines reflect treatment advances. Rheumatology News 2011 April:1,18-9.

4. Rothman Schonfeld, A. Systemic JIA guidelines urged early treatment. Rheumatology News 2011 April: 8,19.

5. Holliman, K. New guidance for rheumatologists who treat JIA. The Rheumatologist 2011 April: 60-2.

6. Eustice, C. ACR recommendations for the treatment of juvenile idiopathic arthritis. About.com 2011 April 14. http://arthritis.about.com/b/2011/04/24/acr-recommendations-for-the-treatment-of-juvenile-idiopathic-arthritis.htm

7. Walker, T. New treatment guidelines strongly endorse use of biologic agents for many children with arthritis refractory to methotrexate. Formulary 2011 May: 157-8.

[Covering the scientific meeting abstract: Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Delzell E, Kim H, Saag KG, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment: an observational study of national US Medicaid administrative claims data [abstract]. Arthritis Rheum 2010;62 Suppl 10:S871]

1. Splete, H. Cancer risk doubled in children with JIA. Rheumatology News 2011 Jan:24. http://www.internalmedicinenews.com/single-view/cancer-risk-doubled-in-children-with-jia/a15edc493b.html

2. Davis, J. Study shows no link to TNF inhibitors and cancer in JIA. Arthritis Today 2010. http://www.arthritistoday.org/news/anti-tnf-biologics-juvenile-arthritis-cancer102.php


Page 39

[Covering the published manuscript: Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580-88.]

1. Axtell, B. Steroid injection first, best for knee. Kid’s Get Arthritis Too 2008 Jan/Feb:7. [Covering the development of a new Pediatric Rheumatology clinic at the University of Alabama at Birmingham/Children’s Hospital of Alabama.]

1. Valesco, A. Specialists in juvenile arthritis start at Children’s. Birmingham News 2007 Sept 12. http://blog.al.com/spotnews/2007/09/specialists_in_juvenile_arthri.html

2. Lockridge, D. Pediatric rheumatology comes to Birmingham. Birmingham Medical News 2007 Dec. http://www.birminghammedicalnews.com/news.php?viewStory=1044

3. Valesco, A. Center celebrates second birthday, addition of third doctor for children with arthritis. Birmingham News 2009 Sept 10. http://www.al.com/news/birminghamnews/metro.ssf?/base/news/1252570531170670.xml&coll=2

Documents

Curriculum Vitae · 2018. 6. 11. · Curriculum Vitae Page 2 . Development of systemic JIA patient simulation CME modules, 2017 . UCB . Safety Officer, Data Safety Monitoring Board,